Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Capricor Therapeutics Inc. (CAPR) stock gains during current market trading. Here’s what’s happening?

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Capricor Therapeutics Inc. (NASDAQ: CAPR) stock surges by 17.13% in the current market trading session. Capricor Medicines is a biotechnology firm specializing in the development of cell and exosome-based therapeutics and vaccines for the treatment and prevention of a wide range of illnesses.

CAPR stock’ Current Update

Capricor Therapeutics stated today that during this year’s World Muscle Society Virtual Congress, they will report final data from its HOPE-2 clinical study with asset CAP-1002 (WMS). HOPE-2 is a randomized, double-blind, placebo-controlled Phase II clinical study performed at nine sites around the United States in 20 patients with late-stage Duchenne muscular dystrophy (DMD). Participants attending the conference will be able to view Capricor’s presentation. The World Muscle Society Virtual Congress will be held online from September 20 to 24 in 2021. During his oral presentation, Dr. Craig McDonald, Capricor’s Principal Investigator for the HOPE-2 trial, will be there to evaluate the findings.

In Capricor’s HOPE-2 study, 80% of patients were non-ambulant, and the age range of participants was about 14 years. All CAP-1002 individuals were on standard of care medicines, which included corticosteroids, and the primary effectiveness endpoint was assessed by the Performance of the Upper Limb (PUL) 1.2 mid-level. More than what is mediated by steroids, individuals with DMD seldom observe function recovery or stabilization.

Dr. Linda Marbán, Chief Executive Officer of Capricor commented,

They are excited to report the final results of their HOPE-2 clinical trial at the World Muscle Society Meeting this year. While their topline data from last year was encouraging, they feel the final data supports CAP-1002’s influence on DMD development in non-ambulant patients far more. While gene treatments have shown potential for improving DMD results, this therapy paradigm will almost definitely involve a multi-pronged approach, particularly in elderly patients with more severe illness. This is where CAP-1002’s immunomodulatory and anti-fibrotic mode of action, which stimulates skeletal and cardiac muscle regeneration, may come in handy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam